C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy-Reference-Cited by-同舟云学术

C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy

Published:2017-07-27 Issue:22 Volume:123 Page:4411-4418
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Epperla Narendranath¹^ORCID,Maddocks Kami J.²,Salhab Mohammed³,Chavez Julio C.⁴,Reddy Nishitha⁵,Karmali Reem⁶,Umyarova Elvira⁷,Bachanova Veronika⁸^ORCID,Costa Cristiana⁹,Glenn Martha¹⁰,Calzada Oscar¹¹,Xavier Ana C.¹²^ORCID,Zhou Zheng³,Hossain Nasheed M.¹³,Hernandez-Ilizaliturri Francisco J.¹⁴,Al-Mansour Zeina¹⁵,Barta Stefan K.¹³,Chhabra Saurabh¹,Lansigan Frederick¹⁶,Mehta Amitkumar¹²,Jaglal Michael V.⁴,Evans Andrew¹⁵,Flowers Christopher R.¹¹^ORCID,Cohen Jonathon B.¹¹,Fenske Timothy S.¹,Hamadani Mehdi¹,Costa Luciano J.¹²

Affiliation:

1. Department of Hematology/Oncology; Medical College of Wisconsin; Milwaukee Wisconsin

2. Department of Hematology; Ohio State University; Columbus Ohio

3. Children's Medical Center; University of Massachusetts Memorial Medical Center; Worcester Massachusetts

4. Department of Malignant Hematology; Moffitt Cancer Center; Tampa Florida

5. Department of Hematology/Oncology; Vanderbilt University; Nashville Tennessee

6. Department of Hematology, Oncology, and Cell Therapy; Rush University Medical Center; Chicago Illinois

7. Department of Medicine; Medical University of South Carolina; Charleston South Carolina

8. Division of Hematology, Oncology and Transplant, Department of Medicine; University of Minnesota; Minneapolis Minnesota

9. Dartmouth-Hitchcock Medical Center; Lebanon New Hampshire

10. University of Utah School of Medicine; Salt Lake City Utah

11. Winship Cancer Institute; Emory University; Atlanta Georgia

12. Department of Pediatrics; The University of Alabama at Birmingham; Birmingham Alabama

13. Fox Chase Cancer Center; Philadelphia Pennsylvania

14. Department of Medicine; Roswell Park Cancer Center; Buffalo New York

15. Section of Hematology and Oncology, Department of Medicine; Tufts University Medical Center; Boston Massachusetts

16. Department of Hematology Oncology; Darmouth-Hitchcock Medical Center; Lebanon New Hampshire

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference18 articles.

1. Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma;Nitsu;Cancer Sci.,2009

2. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy;Savage;Blood.,2009

3. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL);Klapper;Leukemia.,2008

4. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study;Copie-Bergman;J Clin Oncol.,2009

5. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation;Cuccuini;Blood.,2012

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of Relapsed Refractory Large B-Cell Non-Hodgkin Lymphoma;Advances in Oncology;2024-05

2. Physical Activity Program for the Survival of Elderly Patients With Lymphoma: Study Protocol for Randomized Phase 3 Trial;JMIR Research Protocols;2022-11-25

3. Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era;Frontiers in Immunology;2022-06-01

4. Ki67 Immunohistochemical Expression Level ≥70%, Bulky Presentation ≥7.5 cm, Meningeal Lymphomatosis, and Interim PET ΔSUVmax After 4 Treatment Cycles <71% as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell Lymphoma;Frontiers in Nuclear Medicine;2022-04-07

5. Defining and Treating High-grade B-cell lymphoma, NOS;Blood;2021-09-15